ijms-logo

Journal Browser

Journal Browser

Viral Infections and Cancer: Recent Advances and Future Perspectives (2nd Edition)

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 March 2026) | Viewed by 870

Special Issue Editor

Special Issue Information

Dear Colleagues,

Viral infections account for 15–20% of human cancers, representing the second most important cause of cancer and a major global health concern. Viruses can target major cellular mechanisms and pathways, directly or indirectly contributing to oncogenesis. The mechanism(s) by which viruses cause cancer are complex, and multiple viruses may may be involved in the development of a single cancer type.

Viral oncogenesis can occur through alterations in protein expression, genomic modification, chronic inflammation, and immune suppression. Common examples of virus-induced cancers include cervical squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, Kaposi’s sarcoma, and Burkitt’s lymphoma. Research on the role of viruses in cancer development has also led to the development of vaccines that protect against oncogenic viral infections.

This Special Issue aims to expand current knowledge on cancers caused by viral infections. We welcome experimental studies using in vivo and in vitro models, as well as comprehensive review articles.

Dr. Nabiha Yusuf
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • virus
  • infection
  • cancer
  • immune response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 2278 KB  
Review
Genotoxic Bacteria and Oncogenic Viruses in Colorectal Cancer: Evidence, Gaps, and a Proposed Interaction Model
by Nickolas Salazar-Ulbrich, Darling Haro-Solis, Francisco Aguayo, Claudia Quezada-Monrás, Leonardo Cárcamo, Luis Collado and Diego Carrillo-Beltrán
Int. J. Mol. Sci. 2026, 27(5), 2272; https://doi.org/10.3390/ijms27052272 - 28 Feb 2026
Viewed by 505
Abstract
Colorectal cancer (CRC) remains a significant global health burden, with growing evidence highlighting microbial contributions to its pathogenesis. Certain genotoxigenic bacteria, such as Escherichia coli, Campylobacter jejuni, and Helicobacter pylori, produce virulence factors that induce DNA damage, genomic instability, and [...] Read more.
Colorectal cancer (CRC) remains a significant global health burden, with growing evidence highlighting microbial contributions to its pathogenesis. Certain genotoxigenic bacteria, such as Escherichia coli, Campylobacter jejuni, and Helicobacter pylori, produce virulence factors that induce DNA damage, genomic instability, and chronic inflammation—key features of carcinogenesis. At the same time, viruses such as JC polyomavirus (JCPyV), considered potentially oncogenic, and established oncogenic viruses like Epstein–Barr virus (EBV) and human papillomavirus (HPV) have been detected in colorectal tissues and are linked to cell cycle regulation, apoptosis, and DNA repair through their viral proteins. Intriguingly, recent findings suggest that bacterial genotoxins may promote the reactivation or transcriptional activity of persistent viruses such as JCPyV and EBV, possibly through DNA damage-induced stress and activation of NF-κB- or ATM-dependent signaling pathways. Despite these advances, interactions between oncogenic viruses and bacteria within the colon microbiome remain underexplored. This review integrates current evidence and provides future perspectives for addressing potential genotoxic collaboration between bacteria and viruses that could contribute to colorectal tumorigenesis. Elucidating these interactions could reveal novel biomarkers and therapeutic targets for the prevention and treatment of CRC. Full article
Show Figures

Figure 1

Back to TopTop